RxDoctor Payments Data

Samantha Turmenne

Acute Care · Riverside, RINPI 1881216893

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 25.6% of the total. Reporting peaked in 2022 at $265 and has fallen 58.5% since, to $110 in 2025.

$949in general payments, 2019–2025

Across 19 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$243
  • Johnson & Johnson$234
  • GSK$188
  • Regeneron Healthcare Solutions, Inc.$110
  • Eisai Inc.$104
  • Takeda Pharmaceuticals U.S.A., Inc.$30
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$949 in reported general payments places this provider in the 75th percentile of 66 acute care providers in Rhode Island.

See all acute care providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,967
Medicare patients
155
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide65$41,586
MotegrityPrucalopride Succinate11$6,589
Colestipol Hcl42$4,149
Omeprazole207$3,073
Dicyclomine Hcl85$1,699
Pantoprazole Sodium99$1,300
CholestyramineCholestyramine (With Sugar)25$1,227
Famotidine72$1,069
Esomeprazole Magnesium18$829
Lansoprazole11$488
Amitriptyline Hcl32$388
Metronidazole11$176
Hydrocortisone14$176
Sucralfate15$116
Ondansetron Hcl13$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$243$41,58665 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$30$6,58911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 66 acute care providers in Rhode Island.

Other acute care in Riverside

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →